Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Nuvation Bio (NUVB) Equity Average (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Equity Average for 3 consecutive years, with $315.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 34.65% to $315.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $315.8 million, a 34.65% decrease, with the full-year FY2025 number at $384.8 million, down 28.01% from a year prior.
  • Equity Average was $315.8 million for Q4 2025 at Nuvation Bio, down from $349.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $632.9 million in Q2 2023 to a low of $315.8 million in Q4 2025.
  • A 3-year average of $477.3 million and a median of $441.6 million in 2025 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 38.53% in 2024, then dropped 6.92% in 2025.
  • Nuvation Bio's Equity Average stood at $608.4 million in 2023, then dropped by 20.56% to $483.3 million in 2024, then plummeted by 34.65% to $315.8 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Equity Average are $315.8 million (Q4 2025), $349.4 million (Q3 2025), and $396.2 million (Q2 2025).